Has Jill Nakayama received payments from drug or device companies?

Yes. Drug and device makers reported $2,831 in general payments to Jill Nakayama across 127 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jill Nakayama did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jill Nakayama come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jill Nakayama

Family · Denver, CONPI 1831829332

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 34.6% of the total. 2025 is the largest year on record at $1,611, 3.7 times the $438 reported in 2023. Among family clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,831in general payments, 2019–2025

Across 127 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$978
Novo Nordisk$301
Lilly USA, LLC$297
Viiv Healthcare Company$271
Pfizer$171
Exact Sciences$147
plus $666 from 14 others

What the payments were for

Food & beverage$2,831100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	44	$978
Novo Nordisk	11	$301
Lilly USA, LLC	16	$297
Viiv Healthcare Company	12	$271
Pfizer	9	$171
Exact Sciences	7	$147
Vanda Pharmaceuticals Inc.	2	$140
Shield Therapeutics Inc	3	$85
GSK	4	$80
Exeltis, USA Inc.	4	$65
Gilead	3	$61
Tris Pharma Inc	2	$58
Amgen	2	$35
AstraZeneca	2	$29
Edwards Lifesciences	1	$26
Boston Scientific	1	$23
Phadia US Inc.	1	$21
Phathom Pharmaceuticals, Inc.	1	$15
Irhythm Technologies, Inc.	1	$14
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

QULIPTA$125
Fanapt$118
Wegovy$114

How this compares

$2,831 in reported general payments places this provider in the 90th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado →

Other family in Denver

Katie NadingDenver$28K
Randall McDavidDenver$26K
Kyle OdvodyDenver$24K
Naser Kalani YazdDenver$15K
Kara RobertsonDenver$10K
Katherine RiedlerDenver$8K
Corinne YoungColorado Springs$272K
Margaret MachaffieColorado Springs$97K
April RossGrand Junction$95K
Jeannette LillerColorado Springs$74K

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →